Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Penumbra Inc (NYSE:PEN) CEO and President Adam Elsesser sold a total of 13,870 shares of common stock on June 25, 2025, for approximately $4,026,588. The sales were executed in multiple transactions with prices ranging from $251.26 to $257.12. The medical devices company, currently valued at $9.9 billion, maintains a "GREAT" financial health score according to InvestingPro analysis.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which was established in connection with the expiration of certain stock options and related sales to cover the exercise price and tax obligations. With revenue growing at ~13% and strong liquidity metrics, the company appears positioned for continued growth. Discover more insider trading patterns and 12+ additional ProTips with InvestingPro.
On the same day, Elsesser also exercised options to acquire 27,976 shares of Penumbra common stock at a price of $30 per share, for a total value of $839,280.
Following these transactions, Elsesser directly owns 122,441 shares of Penumbra, and indirectly owns 577,582 shares through the Siegel/Elsesser Revocable Trust.
In other recent news, Penumbra has reported significant financial growth, with sales reaching $324.1 million, marking a 16.3% increase from the previous year, and earnings per share (EPS) soaring to $0.83, a 102.8% rise. These figures surpassed Wall Street estimates, reflecting the company’s strong performance, particularly in the U.S. Thrombectomy segment, which saw a 25% increase in sales. UBS has raised its price target for Penumbra to $330, maintaining a Buy rating, citing the company’s robust growth trajectory and strategic focus. Similarly, Stifel increased its price target to $318, highlighting Penumbra’s impressive first-quarter results for 2025 and raised U.S. Thrombectomy guidance. BTIG also adjusted its price target to $320, underscoring the strong performance in key segments and favorable market position.
Additionally, Piper Sandler analyst Matt O’Brien has expressed optimism about the potential early regulatory approval of Penumbra’s Thunderbolt device, which could further boost the company’s revenue. O’Brien reiterated an overweight rating, noting the anticipated interest from the medical community once the device is available. Investors are closely watching these developments, as an early approval could provide Penumbra with a competitive advantage in the medical device sector. These recent developments indicate a positive outlook for Penumbra, driven by strong financial results and strategic advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.